{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:24:12Z","timestamp":1787840652252,"version":"build-2784847793"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oral pemphigus vulgaris (PV) presents with persistent, painful, nonhealing oral erosions, with a slower treatment response compared to cutaneous lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>To assess the efficacy of adjuvant topical rituximab encapsulated in nanoparticle gel in oral PV. Of 31 oral PV patients recruited, 16 were randomized to rituximab incorporated in calcium alginate nanoparticles (study group) and 15 to calcium alginate nanoparticle gel only (placebo group), applied twice daily on oral erosions for 12 weeks. Both groups, in addition, received oral prednisolone (tapering doses) and azathioprine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the topical rituximab group, 75% of patients and in the placebo group, 86.7% of patients achieved remission (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.65) over 12 weeks of therapy. The median time to remission in the topical rituximab group was 4 weeks, and in the placebo group, it was 8 weeks (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.53). Median oral pemphigus scores showed an earlier reduction in the rituximab group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.52). The median circulating CD20 count was reduced in the topical rituximab group from 100 to 74\/mm\n                      <jats:sup>3<\/jats:sup>\n                      at week 8. In the placebo group, the value increased from 89 to 118\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (intergroup\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.29). A significantly greater number of cases in the topical rituximab group had a negative mucosal CD20 count (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). There was a comparable fall in desmoglein 3 titers in both groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.58). The mean cumulative prednisolone dose was 3567 mg in the topical rituximab group and 3869 mg in the placebo group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.125). No side effects of rituximab were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>A small sample size, and need of pharmacokinetic studies in animal models to assess absorption of rituximab in nanogel formulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>With topical rituximab incorporated in nanogel, there was a trend toward earlier remission, lower total cumulative oral prednisolone dose, earlier improvement in oral pemphigus score, and greater reduction in CD20 count.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_885_24","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T08:01:24Z","timestamp":1750406484000},"page":"586-590","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Efficacy of Adjuvant Topical Rituximab Encapsulated in Nanoparticle Gel in Oral Pemphigus Vulgaris: A Randomized, Double-Blind, Placebo-Controlled, Pilot Study"],"prefix":"10.4103","volume":"16","author":[{"given":"Pratik Rajendra","family":"Mohta","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Khandpur","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Dinda","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudan","family":"Bhat","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Hematology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Kalaivani","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20250703","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus:Recommendations by an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R2-20250703","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed- dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R3-20250703","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R4-20250703","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2012.04.032","article-title":"Topical sirolimus for oral pemphigus vulgaris:Three unresponsive cases","volume":"67","author":"Poot","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250703","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/wrr.12363","article-title":"Platelet-rich plasma for resistant oral erosions of pemphigus vulgaris:A pilot study","volume":"23","author":"EL-Komy","year":"2015","journal-title":"Wound Repair Regen"},{"key":"R6-20250703","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00403-018-1824-x","article-title":"Autologous platelet-rich plasma and triamcinolone acetonide intralesional injection in the treatment of oral erosions of pemphigus vulgaris:A pilot study","volume":"310","author":"El-Komy","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"R7-20250703","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1468-3083.2010.03610.x","article-title":"Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris","volume":"24","author":"Mignogna","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20250703","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/odi.12639","article-title":"Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study","volume":"23","author":"Sultan","year":"2017","journal-title":"Oral Dis"},{"key":"R9-20250703","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.carbpol.2014.09.032","article-title":"Development of alginate microspheres as nystatin carriers for oral mucosa drug delivery","volume":"117","author":"Mart\u00edn","year":"2015","journal-title":"Carbohydr Polym"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_885_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:32Z","timestamp":1787837192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_885_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_885_24","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2024-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}